Dianthus Therapeutics, Inc. (DNTH) Revenue History
Annual and quarterly revenue from 2016 to present
DNTH Revenue Over Time (2016–2025)
DNTH Revenue Growth History
2 of 4 years with positive growth- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- +334.8%
- FY2023 revenue growth
- -56.0%
- FY2024 revenue growth
- +120.6%
- FY2025 revenue growth
- -67.3%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $463K | -60.2% |
| Q4 2025 | $284K | -78.6% |
| Q3 2025 | $396K | -81.8% |
| Q2 2025 | $193K | -89.6% |
| Q1 2025 | $1.2M | +33.1% |
| Q4 2024 | $1.3M | +190.2% |
| Q3 2024 | $2.2M | +135.1% |
| Q2 2024 | $1.9M | +92.3% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
DNTH's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
DNTH Revenue Analysis (2016–2025)
Current Revenue & Growth
As of June 12, 2026, Dianthus Therapeutics, Inc. (DNTH) generated trailing twelve-month (TTM) revenue of $1.3 million, reflecting significant decline in growth of -60.2% year-over-year. The most recent quarter (Q1 2026) recorded $463,000 in revenue, up 63.0% sequentially.
Historical Growth Trajectory
DNTH's historical revenue data shows a 3-year CAGR of -31.8%. Dianthus Therapeutics, Inc.'s highest annual revenue of $6.4 million was recorded in 2022.
Revenue by Segment
DNTH's revenue is primarily driven by License (100%). With over half of revenue concentrated in License, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including BCAB (-81.8% YoY), RCUS (+67.4% YoY), and APLS (+32.6% YoY) — DNTH has underperformed the peer group in revenue growth. Compare DNTH vs BCAB →
DNTH Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 DNTHCurrent | $1M | -60.2% | - | -8739.3% | |
 BCAB | $2M | -81.8% | +36.1% | -2965.3% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 APLS | $1.0B | +32.6% | +32.0% | 5.5% |
DNTH Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.0M | -67.3% | $2.0M | 100.0% | $-177,933,000 | -8739.3% |
| 2024 | $6.2M | +120.6% | $6.2M | 100.0% | $-101,864,000 | -1633.7% |
| 2023 | $2.8M | -56.0% | $2.8M | 100.0% | $-48,174,000 | -1704.7% |
| 2022 | $6.4M | +334.8% | $6.4M | 100.0% | $-29,705,000 | -462.9% |
| 2021 | $1.5M | - | $1.5M | 100.0% | $-13,086,000 | -886.6% |
| 2020 | $0 | - | $-1,978,000 | - | $-78,702,000 | - |
| 2019 | $0 | - | $-1,843,000 | - | $-82,969,000 | - |
| 2018 | $0 | - | $-875,000 | - | $-59,963,000 | - |
| 2017 | $0 | - | $-376,000 | - | $-35,727,000 | - |
| 2016 | $0 | - | $-6,000 | - | $-9,268,000 | - |
What if you invested $1,000 in DNTH back in 2016?
Total return with dividends reinvested · 10+ years of data
Calculate ReturnsHow much would $100/month in DNTH be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs DNTH Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationDNTH vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowDNTH — Frequently Asked Questions
Quick answers to the most common questions about buying DNTH stock.
Is DNTH's revenue growth accelerating or slowing?
DNTH revenue is declining -60.2% year-over-year. TTM revenue fell to $1M, contrasting with the 5-year CAGR of N/A. The reversal reflects either macro headwinds or company-specific challenges.
What is DNTH's revenue history from 2016 to 2026?
Dianthus Therapeutics, Inc. (DNTH) revenue history spans 2016 to 2026. TTM revenue as of 2026 is $1M, growing at -60.2% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is DNTH's long-term revenue growth rate (CAGR)?
Dianthus Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -60.2% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for DNTH.
Why does DNTH's quarterly revenue fluctuate?
DNTH quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Dianthus Therapeutics, Inc.'s revenue data from 2016 to 2026 shows full historical quarterly detail on this page.
How is DNTH's revenue distributed by segment?
DNTH reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does DNTH's revenue compare to industry peers?
Dianthus Therapeutics, Inc. (DNTH) with TTM revenue of $1M and -60.2% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.